What Is Psychedelic-Assisted Therapy?

The short answer

"Psychedelic-assisted therapy" describes a treatment course in which a psychoactive drug is given inside a structured program of psychological support. It is not the drug alone. This page is information only. It does not tell anyone to use any substance, and it gives no amounts or instructions.

Evidence labels used here: promising but limited (some controlled trials, small or short), mixed (results differ by study or outcome), insufficient evidence (too little to judge).

Definition

The US Food and Drug Administration (FDA) uses "psychedelic drug" as shorthand for classic psychedelics, such as psilocybin and LSD, and also for entactogens such as MDMA. [1] That is a regulatory convenience. These are different kinds of substances, as the pages on classic psychedelics and entactogens explain.

In a treatment course, the drug is usually paired with preparation before, support during, and follow-up after. In Oregon's licensed program, for example, "psilocybin services" means preparation, administration and integration sessions provided by a licensed facilitator. [2] The FDA says some development programs include a psychological or behavioral intervention, and that the contribution of the psychotherapy part to any benefit has not been characterized. [1] In plain terms: nobody yet knows how much of a trial result comes from the drug, how much from the therapy, and how much from the combination.

The therapy itself is not one standard method. A systematic review found ad hoc and adapted methods, with differences in therapeutic stance, how directive the therapist is, and how much information is given to patients. [3]

What clinical research settings look like

• MDMA for PTSD (phase 3, 104 adults). Participants had three 90-minute preparation sessions with a two-person therapy team, then three 8-hour dosing sessions about a month apart. Both groups received identical therapy. [4] Scores on a PTSD clinician scale fell by 23.7 points with MDMA-assisted therapy and 14.8 with placebo plus therapy. [5] Seven participants had a severe adverse event (5 of 53 versus 2 of 51), with no serious adverse events reported. [5] The trial was funded by the sponsoring nonprofit, MAPS. [4] Label: promising but limited.
• Psilocybin for major depression (27 adults, waitlist comparison). Two psilocybin sessions were given with about 11 hours of supportive psychotherapy. [6] Depression scores were lower in the immediate-treatment group than in the group still waiting. [6] Small, with a waitlist comparison rather than a placebo. Label: promising but limited.
• Psilocybin for treatment-resistant depression (phase 2, 233 adults). The higher study dose, but not the lower one, beat a 1 mg comparison at 3 weeks. Adverse events occurred in 77% of participants, and suicidal thoughts or self-injury occurred in all dose groups. [7] Label: mixed.

Masking is a recurring problem: strong drug effects can let people guess what they received, which can bias results. [1] The MDMA trial authors noted that treatment expectancy was not measured. [4] See how to read a psychedelic clinical trial and research limits.

A 2020 review concluded the evidence was not then enough for FDA approval of any psychedelic for routine psychiatric use. [8] Regulatory status changes; this page does not state current approval status. Read what is and is not approved.

Licensed services are not the same as clinical treatment

Oregon's program requires no prescription or referral and is limited to adults 21 or older. [2] Psilocybin remains a Schedule I substance under federal law (Oregon Health Authority, read 2026-10-22). [9] A reviewer has also cautioned that psychedelics remain investigational and are not yet appropriate for general clinical use. [10] State-regulated services, trials and approved medicines are three different things. Laws change and this is not legal advice; see legal status by country.

Not the same as retreats

The safeguards described on this page come from research protocols and regulators: screening, trained monitors, medical backup. This page does not assess retreats or other unregulated settings, and nothing here shows that they provide those safeguards. See evaluating retreat claims.

Related guides

• Preparation in clinical settings
• What integration means
• Screening and eligibility
• MDMA: compound guide and psilocybin: compound guide